FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL
The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).